TW's Take: INmune continues to make solid progress on all fronts. The rest of 2021 should have some exciting catalysts with Quellor data, Xpro data and phase 2 starting, and INKmune dosing first patients. We continue to be big...
There are times when stock picking isn't the most important part of your investment strategy. When all that matters is being in the right sector of the market. At those times, traders are looking great and investors, those of...
Earlier this year I was preaching caution. The markets were en fuego and, simply put, this cannot last. While I run pretty fully invested and am looking for long-term gains, I'm not naive. Most people reading this newsletter aren't...
We had the opportunity to meet virtually with INmune Bio (INMB) recently. In that meeting, with their CFO, David Moss, and Director of Neuroscience, CJ Barnum, we discussed the role of inflammation in many diseases and how XPro1595 works...
Last week I wrote about INmune Bio (INMB). In that piece, In Defense of INmune, I discussed the increasing spread between perception of what's going at INmune versus the reality. On Friday it seems someone noticed as the stock...
I invest in "public venture capital" stocks. The typical company around here is early stage, has no revenue and is burning cash on a daily basis. They are not without risk. On the other hand, the potential for each of...
My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It was a long day but certainly well worth the effort. The drive was eerily reminiscent of...
Investing in micro-caps always involves a high degree of risk. This risk can come in many different forms as well. For example, looking at the Risk Factors section on TFF Pharma (TFFP)'s recent 10-K filing they have the following...
Good Morning Vietnam! Okay, I'll confess to exaggerating a little; I neither live nor work in a war zone. It only just felt like someone was taking napalm to my portfolio on a daily basis the last couple weeks....
This is without a doubt the most amazing market of my career. It's obviously a bull market as indexes continue to head higher. But, within the belly of the beast, it's absolutely rocking and rolling. Some of the moves taking...
~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to be shared, especially with Company managements. Thank you. ~ Spent a while on the phone with...
What a crazy way to end a wild month, huh? As GameStop (GME) continued to rally in the face of shorts, Robin Hood required a bailout and individual investors rejoiced in their apparent obliteration of several hedge funds. The carnage...
When you write a newsletter, being speechless is not a great place to be. However, what I'm seeing in the market right now leaves me without words. Is the price action unparalleled in history? Quite possibly. But it sure does...
This morning INmune (INMB) presented data from their phase 1b trial in Alzheimer's Disease and hosted a KOL call to discuss the data. Although it traded higher initially, the stock is now down post the call. This volatility based...
TW's Take: amazing data. INmune is on a path to be part of the solution for Alzheimer's Disease, a massive market. This is incredibly exciting. LA JOLLA, Calif, Jan. 21, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the...
Frequently I hear from investors that something sounds, "too good to be true." And, being honest, more often than not, that's the case. But, not always... I heard that frequently about Atomera (ATOM) when I said it's possible to extrapolate...
This week Eli Lilly (LLY) reported data from their phase 2 Alzheimer's trial, TRAILBLAZER-ALZ. Based on the results of this data, shares in LLY rallied substantially, adding over $20B in market cap. That's not a typo. The market values...
TW's Take: very excited to see this data which will only reinforce and add to the smaller set of outstanding interim data the Company presented last summer. Expect to hear more tangential stories of cognitive benefits on the call....
Nothing seems to be able to get in the way of this bull market. An insurrection in DC? Yawn. The next administration taking on big tech? Nobody cares. Covid-19 running crazy globally? That just means more stimulus and Robin...
They say the best presents come in small packages, right? Well, Santa is delivering this year in a big way. And, the best gifts he's giving investors are in the smallest stocks. We are in the middle of a...
This week saw a continued rally in the market with smaller stocks continuing their outperformance. It has been an impressive run and looks likely, as I mentioned last week, to continue until we get a stimulus package. At that...
November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index climb a whopping 18%. This outpaced the S&P and Nasdaq as smaller companies are really...
The market's rally, especially in small-cap, continued this past week and Tailwinds' stocks participated along with the broader indexes. In particular, performance of our portfolio was led by Anixa (ANIX) on the back of their long-awaited news of an...
On Monday morning, Pfizer (PFE) announced that they have a very effective vaccine for Covid-19. This, combined with what appears to be a clear result in the presidential election, sparked a very strong rally in the stock market. Normally a...
Tailwinds' Take: very positive news for a stock that has been awaiting some. We believe that Quellor will be very effective in reducing cytokine storms and this is the pathway to accelerated approval. LA JOLLA, Calif, Nov. 09, 2020 (GLOBE...

Moving Week

What do Donald Trump and I have in common? We are both in the process of moving... This week we found out that Joe Biden will become the next president of the US. Simultaneously, the Mr. and Mrs. Carlson jumped...
Yesterday afternoon, to my sheer delight, three companies in which I and/or my readers have large holdings all reported earnings at the same time. Very frustrating as I would like to have been on all three calls but instead...
LA JOLLA, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the...
What do I want to say? That's the question that comes into my head every Saturday morning. This newsletter is an opportunity. An opportunity to send a message to thousands of readers. It's a privilege that I don't take...
Having survived the rocky cliffs of Moab, I think I jinxed myself with last week's cover photo asking "What could go wrong?" Turns out we learned the answer on Monday as just about everything in our universe got taken...
Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand at the end of Q3 with the S&P having climbed 8.5% in the quarter and...
After fortuitously sheltering in place on the east coast for seven weeks, we are heading back for CA this week. We seem to have, very thankfully, missed the smoke and clear skies await. Now, if we can survive the...
Tailwinds' Take: to quote CEO, RJ Tesi, "This award reinforces one of INmune Bio’s fundamental drug development tenets – by targeting the underlying biology, you can target a diverse group of diseases caused by inflammation." I believe that INmune's...
The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in jail and I really don't recommend it. It's effective in the short term, but truly...

Hello Fall!

What a difference a week makes. Last Saturday I was writing about an epic (for Tailwinds) stretch of performance and salivating over all the positive catalysts that were on deck for September. This week I'm shellshocked by the sudden...
Tailwinds' Take: good news as INmune's INKmune program, which has shown great early stage data, is now protected. INMB continues to execute on two exciting programs. LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB)...
Tailwinds' Take: great news as we believe Quellor has a great opportunity to not only have a positive impact in Covid-19 but also the data generated could be very important in proving efficacy in combating cytokine release syndrome in...
Okay, I know it's not the official end of August...that takes place on Monday. However, due to the fact that the month is basically over and September will be close to a week over by the next newsletter, I'm...
Stocks continued to climb the proverbial wall of worry last week, with the S&P briefly managing to touch an all-time high and the Russell getting closer to positive territory for the year. Meanwhile, in a move that has many...
Tailwinds' Take: important to obtain a patent for the very large European market. XPro1595 has blockbuster potential for INMB. Very excited to see more Alzheimer's Data in December as well as Covid results sometime even sooner. LA JOLLA, Calif., Aug....
Telehealth was the all the rage this past week. First The Centers for Medicare & Medicaid Services (CMS) is proposing changes to expand telehealth permanently, consistent with the Executive Order on Improving Rural and Telehealth Access that President Trump...
David J. Moss Thank you Malika, and good afternoon everybody. We thank you for joining us for the call for INmune Bio’s second quarter 2020 financial results. With me on the call is RJ Tesi, CEO and cofounder of INmune...
Tailwinds' Take: BTIG banked their recent financing and now is hosting them at a conference. Could research be coming soon? LA JOLLA, Calif, Aug. 03, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology...
Here I am on my first plane flight since Covid became a word used in our everyday vernacular. Things seem pretty much the same with the exception of everyone wearing a face mask. The irony in this is I...
Tailwinds' Take: we view this very favorably as the only "negative" in the INMB story was their lack of capital. They are now funded into 2022. With great data and major milestones awaiting, INMB is poised to be a...
"When they reached the end of their 12 week trial, this family was willing to do anything to remain on the drug...because it had been such a profound change," Dr. Rosalyn Lai Alzheimer's is an incredibly debilitating disease. It slowly...
Tailwinds' Take: this is very positive data. The reduction in white matter is particularly encouraging as there is direct correlation between this reduction and an improvement in cognition, which is the holy grail in Alzheimer's.  LA JOLLA, Calif., July 13,...
Tailwinds' Take: with the trial being open-label, INmune has been able to see the data all along. Therefore, one can assume that they are very excited about the results to be hosting a discussion thereof prior to AAIC 2020....
With June closing out, we can now reflect on what was the best quarter the stock market has seen since the turn of the century. From the depths of despair to seeing the indexes recoup most if not all...
When you receive this newsletter, it will be June 21st, the official start of summer. Typically for stocks you have a summer doldrums, "sell in May and go away" being the mantra that long-time traders have bandied about for...
Tailwinds' Take: first-in-man for their second product line is a major accomplishment for the Company. By targeting the innate immune system's NK cells, INKmune has great potential across a broad range of cancers. LA JOLLA, Calif., June 11, 2020 (GLOBE...
Tailwinds' Take: the scientific publication linked here is a great summation of the potential of NK cells in fighting cancer. INMB's INKmune program has similar attributes to CAR-T but with a better safety profile. And, at a fraction of...
As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm not sure how much value I can add. That is, if you've read my newsletters...
Tailwinds' Take: submitting an IND for Covid-19 this month is the biggest potential near term driver, but there are lots of shots on goal here for a small company. Next up after this is a peek at interim Alzheimer's...
Tailwinds' Take: further evidence of the broad-scale applications possible by reducing soluble TNF and associated inflammation. INB03 has the potential to be used in multiple therapies beyond oncology, including Nash, Alzheimers and COVID-19. LA JOLLA, Calif., May 11, 2020 (GLOBE...
The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional investors with whom I speak. Here in my home of Marin County, we expect restaurants...
Well, I've been expecting it and it appears that it's here. The market put up one of its best months ever in April, but starting on Thursday my anticipated end of the rally kicked off. I'm saying it here...
CoronaVirus is not only the buzzword for the whole market both on the negative side as business falls off a cliff, and positively as some companies look for a cure. It seems like most everyone in healthcare is looking...
While the markets may not have had the most volatile week of the year, nor come close, it was a very topsy-turvy five days for Tailwinds. A couple stocks up over 30% and a couple down over 50%. Meanwhile,...
Tailwinds' Take: more evidence on the negative role that soluble TNF plays in many diseases. INMB's ability to neutralize soluble TNF without associated immuno-supression makes them a potential part of the therapy not only in breast cancer, but other...
Tailwinds' Take: patents show the uniqueness of INKmune, which is set to start two clinical trials this year. INMB is one of the most exciting opportunities we see in the marketplace. LA JOLLA, Calif., April 22, 2020 (GLOBE NEWSWIRE) --...
INmune Bio DN-TNF Clinical Trial, Complications of Cytokine Storm Caused by COVID-19 April 20, 2020 Presenter R.J. Tesi, CEO and Chief Medical Officer David Moss, CFO Q&A Participants John Aschoff - Roth Capital Michael Carmia - BTIG Jason McCarthy - Maxim Group Mikal Kaiser - BTIG R.K. - H.C. Wainwright Carl...
Monday morning, INmune Bio (INMB) announced that they were pursuing a clinical program to determine if the Company’s TNF Inhibitor (DN-TNF) platform could help prevent complications of cytokine storm caused by COVID-19. This is potentially a breakthrough therapy for...
Tailwinds' Take: this Phase II trial is going to happen quickly. Inflammation is a big part of the problems associated with CV19 and INmune's DN-TNF platform could be ideally positioned to be a part of saving lives. We are...
Another great week in the market. The economy is in free-fall, unemployment is skyrocketing and stocks can't stop going up. How is this possible? Well, as many savvy investors have repeated numerous times over the years, don't fight the...

IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would likely sell off with the democratic socialist in charge, but more so by the concern...
INmune Bio, Inc. Fourth Quarter and Full Year 2019 Earnings Call March 11, 2020, 11 AM  Presenters Landon Baretto, Moderator Raymond J. Tesi, MD, CEO David J. Moss, CFO Q&A Participants John Aschoff, Roth Capital Markets Swayampakula Ramakanth, H.C. Wainwright Carl Byrnes, Northland Securities Daniel Carlson, Tailwinds...
INmune Bio (INMB) is developing a drug targeting the innate immune system and, specifically, its role in the development of chronic inflammation as humans age. Their drug XPro1595 has recently entered a phase 1 trial; a trial that we...
This feels like a very strange time in the market. Usually markets overreact to news. Violent swings to extreme levels are the common occurrence around major market moving events. The coronavirus would appear to be one of these situations....
Lots going on in Tailwinds' universe recently. Here I recap conversations and observations from the prior week's trading... This screen shot says it all...if Druck loves small cap, then I'm saying we're in the right space at the right time. HyreCar...
R.J.: So, hello everybody, I'm R.J. Tesi. I'm the CEO and Acting Chief Medical Officer of Inmune Bio, and today I'll be hosting this bench to bedside, free, CTAD webinar highlighting alternative approaches to treatment of Alzheimer's disease....
Tailwinds' Take: yet another disease where neuro-inflammation plays a role. The breadth of potential treatments for this product is staggering. LA JOLLA, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments...
On Thursday this week, as we finished dinner I looked out the window and the sky was on fire. It was quite possibly the most amazing sunset I've seen from our house and was a great way to end...
In December of 2019, INmune Bio (INMB) commenced dosing of humans in a Phase 1b trial of XPro1595 (XPro), a drug targeting Alzheimer’s Disease. This trial is an 18 patient trial that is designed to run for 12 weeks...
What a difference a year makes. Christmas 2018 marked a time of anguish for investors. The market was in the toilet and, for us small cap investors, it was particularly painful. There seemed to be zero bids out there...
Tailwinds' Take: more solid data that should translate very well into humans. Remember, INmune has an ongoing Phase 1b trial in Alzheimer's Disease right now with results expected before the end of Q2. This data bodes well for those...
Tailwinds' Take: this is a very positive step for this platform. Next steps here are to start a Phase IIa open-label trial next summer, with expected results about 12 months after dosing patients. Herceptin is a relatively uncrowded space...
We are initiating coverage today on INmune Bio (Nasdaq: INMB). According to the Company, INmune (INMB) is “Reprogramming the Innate Immune System for the Treatment of Diseases”. On the surface, this sounds like a fairly standard biotech tagline, but...
Tailwinds' Take: this trial looks poised for success as XPro1595 is known to be safe and reduce inflammation, the endpoints for this trial design.  LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB), an immunology...
LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today its will host a live webinar on...
Those who know me well are well aware that Wednesdays are my favorite night of the week. That's the night I go out mountain biking with The Gestalt Haus Gang, ending up at a similarly-named (mountain) biker bar tipping...
LA JOLLA, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today announced that Marcia Allen has joined the company’s board as...
LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the third quarter ended September 30,...
LA JOLLA, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today that Dr. Malú Tansey presented data that show the use...
LA JOLLA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported positive preliminary data today during a presentation at Cambridge Healthtech...
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.